CCL2 and neoplasm: Other cytokines (CCL2, IFNγ, IL-12, IL-10, TNFα, IL-4, and IL-1β) evaluated were not significantly changed, suggesting that additional unidentified tumor-derived soluble factors promote alternative activation in BMDMs.